Valentina Fava

Valentina Fava

Auto-generated profile, based on publicly available information

Valentina Fava

Department of General Surgery and Medical Surgical Specialties, Gynecological Clinic of the Policlinico Universitario, Via S.Sofia 78, 95124, Catania, Italy

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
SCSalvatore Caruso
Salvatore Caruso
MIMarco Iraci
Marco Iraci
SCStefano Cianci
Stefano Cianci
Salvatore Giovanni VitaleSalvatore Giovanni Vitale
Salvatore Giovanni Vitale
VFValentina Fava
Valentina Fava
ACAntonio Cianci
Antonio Cianci
Purpose: The aim of this prospective study was to evaluate quality of life (QoL) and sexual function of women affected by endometriosis pain treated with Dienogest (DNG) for 24 months. Patients and methods: Fifty-four women constituted the study group and were given DNG 2 mg/daily; 38 women were given non-steroidal anti-inflammatory drugs (NSAIDs) and constituted the control group. To define endometriosis-associated pelvic pain, dysmenorrhea and dyspareunia the Visual Analogic Scale (VAS) was used. The Short Form-36 (SF-36), the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess the QoL, sexual function and the sexual distress, respectively. The study included five follow-ups at 3, 6, 12, 18 and 24 months. Results: Slight improvements in chronic pelvic pain, dysmenorrhea and dyspareunia were observed in the study group at 3 months (p<0.05) and improved more from 6 to 24 months of DNG treatment (p<0.001). QoL improved with a similar trend: at 3 months the improvement was significant in several categories (p<0.05), and from 6 to 24 months in all categories (p<0.001). The FSFI score did not change at the 3 month follow-up (p=not significant [NS]) but it improved from 6 to 24 months (p<0.001). A similar trend was observed for the FSDS score (p<0.001). No change was observed in the control group (p=NS). Conclusion: Long-term treatment with DNG 2 mg once-daily in women with endometriosis-associated pelvic pain may have positive effects on the QoL and sexual life, confirming the observations of the previous study on the first 6 months of treatment.


4 September 2015 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
SCSalvatore Caruso
Salvatore Caruso
MIM. Iraci
M. Iraci
SCStefano Cianci
Stefano Cianci
ECE. Casella
E. Casella
VFV. Fava
V. Fava
ACA. Cianci
A. Cianci

1 July 2017 in Journal of Women's Health
Verified
Journal Article
Closed access
SCSalvatore Caruso
Salvatore Caruso
SCStefano Cianci
Stefano Cianci
MCMaria Cariola
Maria Cariola
VFValentina Fava
Valentina Fava
SPSalvatore Di Pasqua
Salvatore Di Pasqua
ACAntonio Cianci
Antonio Cianci
Objectives: To investigate the effects of a combined oral contraceptive (COC) containing 17β-estradiol (E2) 1.5 mg and nomegestrol acetate 2.5 mg (NOMAC/E2) on the sexual health of women affected by low sexual desire due to COCs containing ethinylestradiol. Materials and Methods: Eighty-three women (age range 19–32) participated in the study. Sex hormone-binding globulin (SHBG), total testosterone (TT), and free androgen index (FAI) were measured. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) questionnaires were used to assess sexual function and distress, respectively. Hormonal levels were measured and questionnaires were administered before the women switched COC NOMAC/E2 usage (baseline) and at the 3-month (first) and 6-month (second) follow-ups. Results: SHBG reduction (p < 0.001), TT (p < 0.05), and FAI increases (p < 0.001) were observed during the first and second follow-ups with respect to baseline values. Sexual desire increased from baseline to the first and second follow-ups (p < 0.001). At baseline, the total FSFI score was 22 ± 1.5 and the FSDS score was 16.6 ± 1.3, both indicating sexual dysfunction with sexual distress. At the first follow-up, the total FSFI score and the FSDS score increased toward sexual health values, being 28.3 ± 1.6 and 12.1 ± 1.5, respectively (p < 0.001). At the second follow-up, the FSFI score had risen to 30.6 ± 1.3 (p < 0.001) and the FSDS score had dropped to 8.3 ± 1.4 (p < 0.001). Conclusions: COCs containing E2 are an innovation that could help women to not suffer from low sexual desire during hypoandrogenic COC usage.

14 June 2016 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
SCSalvatore Caruso
Salvatore Caruso
SCStefano Cianci
Stefano Cianci
MCM. Cariola
M. Cariola
VFV. Fava
V. Fava
ARAgnese Maria Chiara Rapisarda
Agnese Maria Chiara Rapisarda
ACA. Cianci
A. Cianci

27 July 2017 in Gynecological Endocrinology
Verified
Journal Article
Closed access
SCSalvatore Caruso
Salvatore Caruso
DMDiletta Mauro
Diletta Mauro
MCMaria Cariola
Maria Cariola
VFValentina Fava
Valentina Fava
ARAgnese Maria Chiara Rapisarda
Agnese Maria Chiara Rapisarda
ACAntonio Cianci
Antonio Cianci
The aim of the study was to verify the efficacy of vulvar Visnadine spray in premenopausal women affected by female sexual arousal disorder (FSAD). Thirty-eight women aged 25–40 years affected by FSAD were enrolled in the randomized crossover study, by two possible sequences: on-demand, washout, daily (A sequence); and daily, washout, on-demand (B sequence). The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) were used to assess sexual function and sexual distress, respectively. Color Doppler ultrasonography was used to measure clitoral blood flow. The study had two follow-ups at 30 (T1) and 60 days (T2). Thirty-one women completed the study. Mean (SD) sexual activity and vulvar Visnadine spray usage was 1 ± 0.9 weekly during on-demand administration for both the sequences (Vs T0, p = NS). The mean sexual activity during daily usage was 2 ± 0.9 (Vs T0, p < .004) and 2 ± 0.8 (Vs T0, p < .001) for A and B sequences, respectively. FSFI total score, particularly genital arousal, improved more during the daily than during on-demand phases of both sequences (p < .001). Finally, clitoral blood flow improved significantly during daily usage of both the sequences (p < .001). Our study suggests that vulvar Visnadine spray could improve sexual performance of women affected by FSAD, producing changes in subjective and objective sexual aspects.